CORONA Remedies
Ticker > Company >

CORONA Remedies share price

CORONA Remedies Ltd.

NSE: CORONA BSE: 544644 SECTOR: Pharmaceuticals & Drugs  1.21 K   4   4

1458.80
+28.40 (1.99%)
NSE: Today, 11:54 AM

Price Summary

Today's High

₹ 1477

Today's Low

₹ 1435.4

52 Week High

₹ 1524

52 Week Low

₹ 1336.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 8922.03 Cr.

Enterprise Value

₹ 8915.46 Cr.

No. of Shares

6.12 Cr.

P/E

59.86

P/B

13.54

Face Value

₹ 10

Div. Yield

0.5 %

Book Value (TTM)

₹  107.76

CASH

₹ 69.27 Cr.

DEBT

₹ 62.69 Cr.

Promoter Holding

69 %

EPS (TTM)

₹  24.37

Sales Growth

17.93%

ROE

27.45 %

ROCE

32.55%

Profit Growth

64.7 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year17.93%
3 Year24.68%
5 YearNA

Profit Growth

1 Year64.7%
3 Year620.88%
5 YearNA

ROE%

1 Year27.45%
3 Year23.69%
5 Year18.34%

ROCE %

1 Year32.55%
3 Year29.51%
5 Year22.8%

Debt/Equity

0.1035

Price to Cash Flow

46.84

Interest Cover Ratio

19.6854

CFO/PAT (5 Yr. Avg.)

1.59175066989272

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2025 69.00 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 620.88000039418% for the Past 3 years.
  • The company has shown a good revenue growth of 24.6772521227509% for the Past 3 years.
  • The company has significantly decreased its debt by 71.4467 Cr.
  • Company has been maintaining healthy ROE of 23.6919333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 29.5065333333333% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 19.6854.
  • Company’s PEG ratio is 0.925233574020214.
  • The company has an efficient Cash Conversion Cycle of -132.0921 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.59175066989272.
  • The company has a high promoter holding of 69%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 23.1816213540532.

 Limitations

  • The company is trading at a high EV/EBITDA of 36.2378.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2025
Net Sales 361.13
Total Expenditure 282.66
Operating Profit 78.47
Other Income 2.27
Interest 1.93
Depreciation 9.2
Exceptional Items 0
Profit Before Tax 69.61
Tax 17.46
Profit After Tax 52.15
Adjusted EPS (Rs) 8.53

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 576.16 617.33 884.05 1014.47 1196.42
Total Expenditure 470.78 599.51 756.07 859.74 956.44
Operating Profit 105.39 17.82 127.98 154.74 239.98
Other Income 4.94 6.6 7.05 6.46 5.94
Interest 2.01 4.73 4.27 14.44 10.6
Depreciation 15.89 20.48 20.1 28.28 37.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 92.43 -0.8 110.66 118.48 198.15
Tax 22.49 -0.4 25.96 27.98 49.1
Net Profit 69.95 -0.4 84.7 90.5 149.05
Adjusted EPS (Rs.) 13.7 -0.3 13.85 14.8 24.37

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 5.03 51.05 61.55 61.16 61.16
Total Reserves 332.8 269.86 346.75 419.02 544.57
Borrowings 31.82 16.54 0 67 16
Other N/C liabilities 23.09 22.29 44.88 58.98 67.92
Current liabilities 191.47 193.92 209.26 268.81 327.1
Total Liabilities 584.21 553.65 662.43 874.96 1016.75
Assets
Net Block 164.4 161.76 184.6 383.7 369.88
Capital WIP 0 14.23 64.71 120.59 185.95
Intangible WIP 0 0 0 0 0
Investments 7.06 7.07 25.3 25.31 25.33
Loans & Advances 1.18 4.21 9.54 8.56 9.1
Other N/C Assets 29 36.71 14.91 2.26 0.1
Current Assets 382.57 329.68 363.38 334.54 426.38
Total Assets 584.21 553.65 662.43 874.96 1016.75
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 92.43 -0.8 110.66 118.48 198.15
Adjustment 28.87 20.34 22.78 46.87 52.69
Changes in Assets & Liabilities -14.53 79.66 -4.91 9.32 -17.06
Tax Paid -27.61 -1.5 -25.82 -17.91 -43.28
Operating Cash Flow 79.16 97.71 102.7 156.76 190.49
Investing Cash Flow -102.12 -65.81 -50.28 -266.64 -83.84
Financing Cash Flow 0.09 -29.86 -44.75 98.54 -106.59
Net Cash Flow -22.86 2.04 7.67 -11.34 0.07

Corporate Actions

Investors Details

PARTICULARS Dec 2025%
promoters 69.00
ankurbhai k mehta 22.00
brinda ankur mehta 2.00
dipaben niravkumar mehta 2.00
kirtikumar laxmidas mehta... 20.00
minaxi kirtikumar mehta 1.00
nirav kirtikumar mehta 22.00
PARTICULARS Dec 2025%
investors 31.00
sepia investments limited... 19.76

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

CORONA Remedies Stock Price Analysis and Quick Research Report. Is CORONA Remedies an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse CORONA Remedies. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). CORONA Remedies has a PE ratio of 58.6951169470661 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. CORONA Remedies has ROA of 15.7579% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. CORONA Remedies has a Current ratio of 1.3035.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. CORONA Remedies has a ROE of 27.4513%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. CORONA Remedies has a Debt to Equity ratio of 0.1035 which means that the company has low proportion of debt in its capital.

  • Sales growth: CORONA Remedies has reported revenue growth of 17.9345% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of CORONA Remedies for the current financial year is 20.0578444673722%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for CORONA Remedies is Rs 7.31 and the yield is 0.5121%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of CORONA Remedies is Rs 24.37. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of CORONA Remedies in Ticker for free. Also, one can get the intrinsic value of CORONA Remedies by using Valuation Calculators, which are available with a Finology ONE subscription. 

CORONA Remedies FAQs

Q1. What is CORONA Remedies share price today?
Ans: The current share price of CORONA Remedies is Rs 1430.4.

Q2. What is the market capitalisation of CORONA Remedies?
Ans: CORONA Remedies has a market capitalisation of Rs 8748.33898752 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of CORONA Remedies?
Ans: The PE ratio of CORONA Remedies is 58.6951169470661 and the P/B ratio of CORONA Remedies is 13.2739667297081, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of CORONA Remedies share?
Ans: The 52-week high share price of CORONA Remedies is Rs 1524, and the 52-week low share price of CORONA Remedies is Rs 1336.6.

Q5. Does CORONA Remedies pay dividends?
Ans: Currently, CORONA Remedies pays dividends. Dividend yield of CORONA Remedies is around 0.5121%.

Q6. What are the face value and book value of CORONA Remedies shares?
Ans: The face value of CORONA Remedies shares is Rs 10, while the book value per share of CORONA Remedies is around Rs 107.7598. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of CORONA Remedies?
Ans: CORONA Remedies has a total debt of Rs 62.6949 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of CORONA Remedies?
Ans: The ROE of CORONA Remedies is 27.4513% and ROCE of CORONA Remedies is 32.5478%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is CORONA Remedies a good buy for the long term?
Ans: The CORONA Remedies long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is CORONA Remedies undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the CORONA Remedies appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check CORONA Remedies’s financials?
Ans: You can review CORONA Remedies’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about CORONA Remedies

Corona Remedies Share Price, Business Overview & News

Corona Remedies Limited made a strong debut on the stock exchanges today, December 15, 2025. A rapidly growing pharmaceutical company, Corona Remedies specialises in chronic and semi-chronic therapies, manufacturing branded formulations for segments like Women’s Health, Cardio-Diabetic care, and Pain Management. The stock listed at a significant premium to its issue price, reflecting robust investor confidence.

Corona Remedies Share Price & Listing Performance

Corona Remedies shares listed on the BSE and NSE today at Rs 1,452, a premium of approximately 36.72% over its IPO issue price of Rs 1,062. The stock demonstrated high volatility and strong buying interest post-listing, touching an intraday high of nearly Rs 1,497.80.

  • Listing Date: December 15, 2025

  • IPO Issue Price: Rs 1,062 per share

  • Listing Price: Rs 1,452 per share (36.72% Premium)

  • Intraday High: ~Rs 1,497.80

  • Market Cap: Approx. Rs 8,800 Crore+ (based on current trading price)

The Business of Corona Remedies: How It Earns

Corona Remedies operates as a domestic-focused pharmaceutical company with a unique "middle of the pyramid" strategy. Its business model avoids the volatility of generic exports, focusing instead on building strong prescription loyalty with specialist doctors in urban and semi-urban India.

  • Core Manufacturing: The company develops and manufactures a wide array of high-quality pharmaceutical formulations. Its state-of-the-art facilities produce tablets, capsules, and syrups that cater to critical therapeutic gaps.

  • Diverse Product Portfolio: Corona Remedies manages over 70 brands across multiple therapeutic areas. Its "Engine Brands" drive significant revenue and include:

    • Women's Health: Brands like Fostine and Menodac (acquired from Bayer India) address infertility and menopausal management.

    • Cardio-Diabetic: Cor-9 is a leading brand for managing cardiovascular health.

    • Pain Management: Myoril is a widely prescribed muscle relaxant.

  • Revenue Drivers: The company earns revenue primarily through domestic sales of its branded formulations. Its growth is fueled by a mix of organic product launches and strategic acquisitions of high-value legacy brands from MNCs like Abbott and GSK. This dual engine ensures steady cash flow and market expansion.

Major News & Developments

  • IPO Success: The Corona Remedies IPO, which closed on December 10, 2025, saw exceptional demand, subscribed approximately 137 times. The Qualified Institutional Buyers (QIB) portion was subscribed over 275 times, indicating strong institutional backing.

  • Fund Utilisation: The IPO was an Offer for Sale (OFS) of Rs 655.37 Crore by existing shareholders. While the company will not receive proceeds directly from this issue, the listing provides liquidity and enhances visibility, positioning it for future capital raising if needed.

  • Strategic Expansion: Recent acquisitions of brands from Bayer and Abbott have strengthened its portfolio, allowing it to enter new niches in gynaecology and cardiology with established products that have immediate brand recall.

What You Can Find on This Company Page

This page is your complete resource for all information related to Corona Remedies Limited. Here’s what you can access:

  • Live Corona Remedies Share Price: Track real-time price movements, volume, and price charts.

  • Financial Performance: Access quarterly results, EBITDA margins, and revenue growth trends post-listing.

  • Shareholding Pattern: View the post-IPO ownership structure, including promoter holdings (approx. 69%) and institutional stakes.

  • Latest News: Stay updated on new product launches, acquisition announcements, and regulatory approvals.

  • Peer Comparison: Compare Corona Remedies’ valuation (P/E, P/B) and performance against other domestic pharma peers.

Frequently Asked Questions (FAQs)

Q1: What does Corona Remedies manufacture?
Corona Remedies manufactures branded pharmaceutical formulations, focusing on Women’s Health, Cardiology, Diabetology, and Pain Management. Key brands include Fostine, Cor-9, and Myoril.

Q2: When did Corona Remedies list on the stock market?
Corona Remedies shares were listed on the NSE and BSE on December 15, 2025.

Q3: Was the Corona Remedies IPO oversubscribed?
Yes, the IPO was heavily oversubscribed, with a total subscription of approximately 137 times, driven by massive demand from institutional investors.

Q4: What is the market cap of Corona Remedies?
As of its listing day, the market capitalisation stands at approximately Rs 8,800 Crore, reflecting the market's positive reception to its business model.

Read More
X